



## **NEWS RELEASE**

For Immediate Release

Contact: Michael P. Hughes (716) 983-3731  
[mhughes@egrethealthcareventures.com](mailto:mhughes@egrethealthcareventures.com)

### **VICORA COMPLETES GLP PRE-CLINICAL STUDY**

#### ***MECHANICAL THROMBECTOMY DEVICE MOVES CLOSER TO FIRST IN HUMAN CLINICAL TRIAL***

**BUFFALO, N.Y. (Monday, January 12, 2026)** – Egret Healthcare Ventures today announced that one of its portfolio companies, Vicora Inc., achieved a significant development milestone as it completed the Good Laboratory Practice (GLP) study for its Vibrato® aspiration system.

Vicora is working on a proprietary catheter system for the treatment of vascular disease, in particular pulmonary embolism and deep vein thrombosis. Future applications involve stroke intervention.

The Vibrato® catheter is a first-of-its-kind, solution designed to remove life-threatening blood clots from the upper legs and lungs with enhanced precision and safety utilizing a vibrating distal end. Developed in Buffalo, N.Y. by a team of leading engineers, physicians, and scientists, the device aims to improve treatment outcomes.

The GLP study was performed by a team of industry leading interventional cardiologists, radiologists, and pathologists, in the endovascular space at the Skirball Center of Innovation (SCI) in New York.

Vicora's clinical advisor Chris Manion, M.D., Interventional Cardiologist, University at Buffalo/Gates Vascular Institute, and multiple other independent physicians, participated in the study as well.

-more-

**PAGE TWO**  
**VICORA/GLP STUDY**  
**January 12, 2026**

The GLP study involved performing the clinical procedure utilizing sterile Vibrato® catheters that are representative of final design and under “worse case” use conditions.

GLP studies provide structured, verifiable evidence that the FDA and other regulatory agencies review for new medical devices, help bridging the gap between lab testing and clinical application in humans.

Skirball is a state-of-the-art pre-clinical research and training center, equipped with the latest technology for testing and validating novel therapies, including devices, robotics, drugs, and biologics. Strategically located near New York City, SCI has been pioneering new treatments and shaping the future in successful therapy development.

Completion of the GLP study puts Vicora on a path for its “first in human” pulmonary embolism (PE) clinical trial, which will commence later this year.

Founded in 2020, Egret’s mission is to identify emerging technologies and help build sustainable and transformational healthcare businesses around them. Egret’s three portfolio companies include Vicora Inc., Ampullae Inc., and the Rookery Labs.

# # #